These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 22110351)

  • 1. Drug development for Alzheimer's disease: recent progress.
    Ji W; Ha I
    Exp Neurobiol; 2010 Dec; 19(3):120-31. PubMed ID: 22110351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amyloid-induced neurofibrillary tangle formation in Alzheimer's disease: insight from transgenic mouse and tissue-culture models.
    Götz J; Schild A; Hoerndli F; Pennanen L
    Int J Dev Neurosci; 2004 Nov; 22(7):453-65. PubMed ID: 15465275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic Strategies Targeting Amyloid-β in Alzheimer's Disease.
    Pinheiro L; Faustino C
    Curr Alzheimer Res; 2019; 16(5):418-452. PubMed ID: 30907320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent therapeutic strategies targeting beta amyloid and tauopathies in Alzheimer's disease.
    Madav Y; Wairkar S; Prabhakar B
    Brain Res Bull; 2019 Mar; 146():171-184. PubMed ID: 30634016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tau Proteins and Tauopathies in Alzheimer's Disease.
    Chong FP; Ng KY; Koh RY; Chye SM
    Cell Mol Neurobiol; 2018 Jul; 38(5):965-980. PubMed ID: 29299792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of tau protein in Alzheimer's disease: The prime pathological player.
    Muralidar S; Ambi SV; Sekaran S; Thirumalai D; Palaniappan B
    Int J Biol Macromol; 2020 Nov; 163():1599-1617. PubMed ID: 32784025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drugs for Targeted Therapies of Alzheimer's Disease.
    Tam C; Wong JH; Ng TB; Tsui SKW; Zuo T
    Curr Med Chem; 2019; 26(2):335-359. PubMed ID: 29714133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic Approach to Alzheimer's Disease: Current Treatments and New Perspectives.
    Pardo-Moreno T; González-Acedo A; Rivas-Domínguez A; García-Morales V; García-Cozar FJ; Ramos-Rodríguez JJ; Melguizo-Rodríguez L
    Pharmaceutics; 2022 May; 14(6):. PubMed ID: 35745693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurobiology of Alzheimer's disease.
    Mohandas E; Rajmohan V; Raghunath B
    Indian J Psychiatry; 2009 Jan; 51(1):55-61. PubMed ID: 19742193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tau in Alzheimer's Disease: Pathological Alterations and an Attractive Therapeutic Target.
    Gu JL; Liu F
    Curr Med Sci; 2020 Dec; 40(6):1009-1021. PubMed ID: 33428128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.
    Panza F; Solfrizzi V; Frisardi V; Imbimbo BP; Capurso C; D'Introno A; Colacicco AM; Seripa D; Vendemiale G; Capurso A; Pilotto A
    Aging Clin Exp Res; 2009 Dec; 21(6):386-406. PubMed ID: 20154508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Recent progress in the development of disease-modifying therapies for Alzheimer's disease].
    Abe K
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2010 Feb; 30(1):1-8. PubMed ID: 20297736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spreading of Pathology in Alzheimer's Disease.
    Lv ZY; Tan CC; Yu JT; Tan L
    Neurotox Res; 2017 Nov; 32(4):707-722. PubMed ID: 28623460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Challenges in the treatment of Alzheimer's disease: recent progress and treatment strategies of pharmaceuticals targeting notable pathological factors.
    Kuo YC; Rajesh R
    Expert Rev Neurother; 2019 Jul; 19(7):623-652. PubMed ID: 31109210
    [No Abstract]   [Full Text] [Related]  

  • 16. Soluble pre-fibrillar tau and β-amyloid species emerge in early human Alzheimer's disease and track disease progression and cognitive decline.
    Koss DJ; Jones G; Cranston A; Gardner H; Kanaan NM; Platt B
    Acta Neuropathol; 2016 Dec; 132(6):875-895. PubMed ID: 27770234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Ambiguous Relationship of Oxidative Stress, Tau Hyperphosphorylation, and Autophagy Dysfunction in Alzheimer's Disease.
    Liu Z; Li T; Li P; Wei N; Zhao Z; Liang H; Ji X; Chen W; Xue M; Wei J
    Oxid Med Cell Longev; 2015; 2015():352723. PubMed ID: 26171115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of mitochondrial dysfunction, oxidative stress and autophagy in progression of Alzheimer's disease.
    Bhatia V; Sharma S
    J Neurol Sci; 2021 Feb; 421():117253. PubMed ID: 33476985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Active full-length DNA Aβ
    Rosenberg RN; Fu M; Lambracht-Washington D
    Alzheimers Res Ther; 2018 Nov; 10(1):115. PubMed ID: 30454039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathological Changes of Tau Related to Alzheimer's Disease.
    Chu D; Liu F
    ACS Chem Neurosci; 2019 Feb; 10(2):931-944. PubMed ID: 30346708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.